Michael Z David1, Robert S Daum2, Arnold S Bayer3, Henry F Chambers4, Vance G Fowler5, Loren G Miller3, Belinda Ostrowsky6, Alison Baesa2, Susan Boyle-Vavra2, Samantha J Eells7, Sylvia Garcia-Houchins8, Philip Gialanella6, Raul Macias-Gil7, Thomas H Rude5, Felicia Ruffin5, Julia J Sieth2, Joann Volinski4, Brad Spellberg9. 1. Department of Medicine and Health Studies Department of Pediatrics, University of Chicago, Illinois. 2. Department of Pediatrics, University of Chicago, Illinois. 3. Department of David Geffen School of Medicine, University of California, Los Angeles (UCLA) Division of Infectious Diseases, Harbor-UCLA Medical Center and the Los Angeles Biomedical Research Institute, Torrance, California. 4. Department of Medicine, University of California, San Francisco. 5. Department of Medicine, Duke University Medical Center, Raleigh-Durham, North Carolina. 6. Montefiore Medical Center/Albert Einstein College of Medicine, New York. 7. Division of Infectious Diseases, Harbor-UCLA Medical Center and the Los Angeles Biomedical Research Institute, Torrance, California. 8. Infection Control Program, University of Chicago Medicine, Illinois. 9. Department of David Geffen School of Medicine, University of California, Los Angeles (UCLA) Division of General Internal Medicine, Harbor-UCLA Medical Center and the Los Angeles Biomedical Research Institute, Torrance, California.
Abstract
BACKGROUND: The incidence of community-onset (CO) methicillin-resistant Staphylococcus aureus (MRSA) bacteremia rose from the late 1990s through the 2000s. However, hospital-onset (HO) MRSA rates have recently declined in the United States and Europe. METHODS: Data were abstracted from infection prevention databases between 1 January 2008 and 31 December 2011 at 5 US academic medical centers to determine the number of single-patient blood cultures positive for MRSA and methicillin-susceptible S. aureus (MSSA) per calendar year, stratified into CO and HO infections. RESULTS: Across the 5 centers, 4171 episodes of bacteremia were identified. Center A (Los Angeles, California) experienced a significant decline in CO-MRSA bacteremia rates (from a peak in 2009 of 0.42 to 0.18 per 1000 patient-days in 2011 [P = .005]), whereas CO-MSSA rates remained stable. Centers B (San Francisco, California), D (Chicago, Illinois), and E (Raleigh-Durham, North Carolina) experienced a stable incidence of CO-MRSA and CO-MSSA bacteremia. In contrast, at center C (New York, New York), the incidence of CO-MRSA increased >3-fold (from 0.11 to 0.34 cases per 1000 patient-days [P < .001]). At most of the sites, HO-MRSA decreased and HO-MSSA rates were stable. USA300 accounted for 52% (104/202) of genotyped MRSA isolates overall, but this varied by center, ranging from 35% to 80%. CONCLUSIONS: CO-MRSA rates and the contribution of USA300 MRSA varied dramatically across diverse geographical areas in the United States. Enhanced infection control efforts are unlikely to account for such variation in CO infection rates. Bioecological and clinical explanations for geographical differences in CO-MRSA bacteremia rates merit further study.
BACKGROUND: The incidence of community-onset (CO) methicillin-resistant Staphylococcus aureus (MRSA) bacteremia rose from the late 1990s through the 2000s. However, hospital-onset (HO) MRSA rates have recently declined in the United States and Europe. METHODS: Data were abstracted from infection prevention databases between 1 January 2008 and 31 December 2011 at 5 US academic medical centers to determine the number of single-patient blood cultures positive for MRSA and methicillin-susceptible S. aureus (MSSA) per calendar year, stratified into CO and HO infections. RESULTS: Across the 5 centers, 4171 episodes of bacteremia were identified. Center A (Los Angeles, California) experienced a significant decline in CO-MRSA bacteremia rates (from a peak in 2009 of 0.42 to 0.18 per 1000 patient-days in 2011 [P = .005]), whereas CO-MSSA rates remained stable. Centers B (San Francisco, California), D (Chicago, Illinois), and E (Raleigh-Durham, North Carolina) experienced a stable incidence of CO-MRSA and CO-MSSA bacteremia. In contrast, at center C (New York, New York), the incidence of CO-MRSA increased >3-fold (from 0.11 to 0.34 cases per 1000 patient-days [P < .001]). At most of the sites, HO-MRSA decreased and HO-MSSA rates were stable. USA300 accounted for 52% (104/202) of genotyped MRSA isolates overall, but this varied by center, ranging from 35% to 80%. CONCLUSIONS: CO-MRSA rates and the contribution of USA300 MRSA varied dramatically across diverse geographical areas in the United States. Enhanced infection control efforts are unlikely to account for such variation in CO infection rates. Bioecological and clinical explanations for geographical differences in CO-MRSA bacteremia rates merit further study.
Authors: Alexander J Kallen; Yi Mu; Sandra Bulens; Arthur Reingold; Susan Petit; Ken Gershman; Susan M Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; John M Townes; William Schaffner; Priti R Patel; Scott K Fridkin Journal: JAMA Date: 2010-08-11 Impact factor: 56.272
Authors: Raymund Dantes; Yi Mu; Ruth Belflower; Deborah Aragon; Ghinwa Dumyati; Lee H Harrison; Fernanda C Lessa; Ruth Lynfield; Joelle Nadle; Susan Petit; Susan M Ray; William Schaffner; John Townes; Scott Fridkin Journal: JAMA Intern Med Date: 2013-11-25 Impact factor: 21.873
Authors: Binh An Diep; Gregory G Stone; Li Basuino; Christopher J Graber; Alita Miller; Shelley-Ann des Etages; Alison Jones; Amy M Palazzolo-Ballance; Françoise Perdreau-Remington; George F Sensabaugh; Frank R DeLeo; Henry F Chambers Journal: J Infect Dis Date: 2008-06-01 Impact factor: 5.226
Authors: R Monina Klevens; Melissa A Morrison; Joelle Nadle; Susan Petit; Ken Gershman; Susan Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; John M Townes; Allen S Craig; Elizabeth R Zell; Gregory E Fosheim; Linda K McDougal; Roberta B Carey; Scott K Fridkin Journal: JAMA Date: 2007-10-17 Impact factor: 56.272
Authors: Rachel C Orscheln; David A Hunstad; Stephanie A Fritz; Jennifer A Loughman; Kimberly Mitchell; Emily K Storch; Monique Gaudreault; Patricia L Sellenriek; Jon R Armstrong; Elaine R Mardis; Gregory A Storch Journal: Clin Infect Dis Date: 2009-08-15 Impact factor: 9.079
Authors: Hajo Grundmann; David M Aanensen; Cees C van den Wijngaard; Brian G Spratt; Dag Harmsen; Alexander W Friedrich Journal: PLoS Med Date: 2010-01-12 Impact factor: 11.069
Authors: Michael W Dunne; Sailaja Puttagunta; Craig R Sprenger; Chris Rubino; Scott Van Wart; James Baldassarre Journal: Antimicrob Agents Chemother Date: 2015-01-05 Impact factor: 5.191
Authors: Sean B Sullivan; Eloise D Austin; Stephania Stump; Barun Mathema; Susan Whittier; Franklin D Lowy; Anne-Catrin Uhlemann Journal: Antimicrob Agents Chemother Date: 2017-06-27 Impact factor: 5.191
Authors: Nicholas A Turner; Batu K Sharma-Kuinkel; Stacey A Maskarinec; Emily M Eichenberger; Pratik P Shah; Manuela Carugati; Thomas L Holland; Vance G Fowler Journal: Nat Rev Microbiol Date: 2019-04 Impact factor: 60.633
Authors: O Perovic; A Singh-Moodley; N P Govender; R Kularatne; A Whitelaw; V Chibabhai; P Naicker; N Mbelle; R Lekalakala; V Quan; C Samuel; E Van Schalkwyk Journal: Eur J Clin Microbiol Infect Dis Date: 2017-08-28 Impact factor: 3.267
Authors: Eloise D Austin; Sean S Sullivan; Nenad Macesic; Monica Mehta; Benjamin A Miko; Saman Nematollahi; Qiuhu Shi; Franklin D Lowy; Anne-Catrin Uhlemann Journal: Clin Infect Dis Date: 2020-04-10 Impact factor: 9.079